Previous Close | 17.07 |
Open | 16.98 |
Bid | 16.81 x 200 |
Ask | 16.84 x 200 |
Day's Range | 16.62 - 17.30 |
52 Week Range | 16.60 - 33.99 |
Volume | |
Avg. Volume | 1,806,161 |
Market Cap | 2.771B |
Beta (5Y Monthly) | 0.39 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.37 |
Earnings Date | May 06, 2024 - May 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 29.40 |
SAN DIEGO, April 19, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common stock and 12,739 restricted stock units ("RSUs") to six new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employme
SAN DIEGO, April 17, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO.
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders, has reported an insider sell transaction.